Intermolecular raises $36M for new chip R&D process

intermolecular.jpgIntermolecular, a new company located in the heart of Silicon Valley’s chip industry (San Jose, Calif.), has launched a technology it says will help semiconductor companies accelerate their research and development of new materials.

Manufacturing breakthroughs in semiconductors are getting more difficult, because of the tiny size of today’s chips. Finding new materials has become the hope for many chip companies. Intermolecular, which has been secretive for almost three years, has raised $36 million to develop its platform, which lets chip companies perform many more tests in R&D.

Early investors were CMEA Ventures and Redpoint Ventures, and U.S. Venture Partners and Symyx Technologies joined more recently.

Here’s a snippet from trade pub Semiconductor International (sorry, no link):

Today, much of the industry’s R&D is done with process equipment intended for volume wafer processing. By contrast, the Intermolecular system is intended to create “massively parallel” processes on a 300 mm wafer, up to 570 distinct process variations on a single wafer, said Gus Pinto, executive vice president of business development.

Intermolecular has worked with “a large logic manufacturer” to synthesize a unique molecule that will be used in copper interconnects at the 32 nm node. “This is a molecule that doesn’t exist anywhere else on Earth today, engineered to have properties of interest to that application,” [chief exec David] Lazovsky said. The Intermolecular approach helped the customer develop a novel integration scheme, including a specific process that allows the integration of the self-assembled monolayer. He called it “one of first implementations of a self-assembled copper monolayer.”

The company says it has more than 700 patents granted or applied for.

Next Story:
Previous Story:

Tags: , , , , ,

Photo of Matt Marshall

About the Author, Matt Marshall

Matt Marshall is editor and CEO of VentureBeat. Follow him on Twitter at @mmarshall, and follow VentureBeat on Twitter at @venturebeat.

  • 700 patent filings at approx $15k each attys fees, never mind USPTO fees, is about 10.5 million in patent costs, likely 50% higher.

    I suspect the bulk of the IP comes from Symyx's large portfolio cross licensed to Intermolecular (all in the family). This is aside of the slightly outlandish claims throughout the press release.

    Doing materials development on 300mm wafers, is beyond any common sense, any sensible financial or technical justification (even for 32nm device integration - you do the materials optimization on small cheap wafers then migrate to 300mm).

    As to a first in self assembly of any kind (including copper monolayers), ALD - Atomic Layer Deposition - is used extensively in industry and IS self assembly incarnate (I can say this as a Process Engineer for 20+ years)

    But some customers will no doubt be willing to shell out the big bucks for speeding something along.

    Excitement ? yawn.....
blog comments powered by Disqus